Cargando…
Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy
Autores principales: | O’Reilly, Emily, Casey, Deborah, Ibrahim, Hisham, McGrath, Alice, McHugh, Tomás, Vairamani, Punitha, Murphy, Jill, Plant, Barry, Murphy, Desmond M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285523/ https://www.ncbi.nlm.nih.gov/pubmed/35844776 http://dx.doi.org/10.2147/JAA.S358321 |
Ejemplares similares
-
Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
por: Walsh, Laura J., et al.
Publicado: (2023) -
Creatine kinase levels in asthma patients receiving interleukin-5
therapy
por: Kavanagh, Grace A., et al.
Publicado: (2022) -
Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE
por: R, Divya, et al.
Publicado: (2020) -
Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2015) -
Metabolomic applied to omalizumab effect in severe asthmatics – a preliminary result
por: Loureiro, Cláudia Chaves, et al.
Publicado: (2013)